Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy.

BACKGROUND & AIMS Gastric cancer (GC) is a heterogeneous disease comprising multiple subtypes that have distinct biological properties and effects in patients. We sought to identify new, intrinsic subtypes of GC by gene expression analysis of a large panel of GC cell lines. We tested if these subtypes might be associated with differences in patient survival times and responses to various standard-of-care cytotoxic drugs. METHODS We analyzed gene expression profiles for 37 GC cell lines to identify intrinsic GC subtypes. These subtypes were validated in primary tumors from 521 patients in 4 independent cohorts, where the subtypes were determined by either expression profiling or subtype-specific immunohistochemical markers (LGALS4, CDH17). In vitro sensitivity to 3 chemotherapy drugs (5-fluorouracil, cisplatin, oxaliplatin) was also assessed. RESULTS Unsupervised cell line analysis identified 2 major intrinsic genomic subtypes (G-INT and G-DIF) that had distinct patterns of gene expression. The intrinsic subtypes, but not subtypes based on Lauren's histopathologic classification, were prognostic of survival, based on univariate and multivariate analysis in multiple patient cohorts. The G-INT cell lines were significantly more sensitive to 5-fluorouracil and oxaliplatin, but more resistant to cisplatin, than the G-DIF cell lines. In patients, intrinsic subtypes were associated with survival time following adjuvant, 5-fluorouracil-based therapy. CONCLUSIONS Intrinsic subtypes of GC, based on distinct patterns of expression, are associated with patient survival and response to chemotherapy. Classification of GC based on intrinsic subtypes might be used to determine prognosis and customize therapy.

[1]  J. Mesirov,et al.  GenePattern 2.0 , 2006, Nature Genetics.

[2]  Xiao-yan Chen,et al.  Frequent loss of membranous E-cadherin in gastric cancers: A cross-talk with Wnt in determining the fate of β-catenin , 2005, Clinical & Experimental Metastasis.

[3]  W. Sauerbrei,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.

[4]  T. Iwaya,et al.  Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration. , 1998, Japanese journal of clinical oncology.

[5]  Gordon K Smyth,et al.  Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2004, Statistical applications in genetics and molecular biology.

[6]  W. Dong,et al.  Lentiviral‐mediated miRNA against liver‐intestine cadherin suppresses tumor growth and invasiveness of human gastric cancer , 2010, Cancer science.

[7]  M. Huflejt,et al.  Galectin-4 in normal tissues and cancer , 2003, Glycoconjugate Journal.

[8]  H. Yoo,et al.  Expression profiling and subtype-specific expression of stomach cancer. , 2003, Cancer research.

[9]  D. Park,et al.  Protein Expression Profiling and Molecular Classification of Gastric Cancer by the Tissue Array Method , 2007, Clinical Cancer Research.

[10]  Scott A. Hundahl,et al.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. , 2001, The New England journal of medicine.

[11]  Yujin Hoshida,et al.  Nearest Template Prediction: A Single-Sample-Based Flexible Class Prediction with Confidence Assessment , 2010, PloS one.

[12]  D. Cunningham,et al.  Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Histological classification of gastric adenocarcinoma for epidemiological research: concordance between pathologists. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[14]  P. Rousseeuw Silhouettes: a graphical aid to the interpretation and validation of cluster analysis , 1987 .

[15]  Yusuke Nakamura,et al.  Comparison of gene-expression profiles between diffuse- and intestinal-type gastric cancers using a genome-wide cDNA microarray , 2004, Oncogene.

[16]  K. Naka,et al.  Expression of the E2F family in human gastrointestinal carcinomas , 1999, International journal of cancer.

[17]  R. Simon,et al.  Patient subsets and variation in therapeutic efficacy. , 1982, British journal of clinical pharmacology.

[18]  Siew Hong Leong,et al.  A combined comparative genomic hybridization and expression microarray analysis of gastric cancer reveals novel molecular subtypes. , 2003, Cancer research.

[19]  Kenji Ikeda,et al.  Gene expression in fixed tissues and outcome in hepatocellular carcinoma. , 2008, The New England journal of medicine.

[20]  H. Sebastian Seung,et al.  Learning the parts of objects by non-negative matrix factorization , 1999, Nature.

[21]  L. Sobin,et al.  The world health organization's histologic classification of gastrointestinal tumors: A commentary on the second edition , 1990, Cancer.

[22]  D. Cox Regression Models and Life-Tables , 1972 .

[23]  E. Chu,et al.  Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. , 2009, Journal of the National Cancer Institute.

[24]  M. Salto‐Tellez,et al.  Reliability of Tissue Microarrays in Detecting Protein Expression and Gene Amplification in Breast Cancer , 2003, Modern Pathology.

[25]  J. Ajani,et al.  Chemoradiation of resected gastric cancer: A 10-year follow-up of the phase III trial INT0116 (SWOG 9008). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Izhak Haviv,et al.  Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer. , 2003, Cancer research.

[27]  P. Laurén,et al.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. , 1965, Acta pathologica et microbiologica Scandinavica.

[28]  Farin Kamangar,et al.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Haerting,et al.  Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  W. Dong,et al.  Altered Expression of a Li-Cadherin in Gastric Cancer and Intestinal Metaplasia , 2007, Digestive Diseases and Sciences.

[31]  S. Ming Gastric carcinoma: A pathobiological classification , 1977 .

[32]  W J Macdonald,et al.  GASTRIC CARCINOMA. , 1912, Canadian Medical Association journal.

[33]  H. Aburatani,et al.  Gene expression profiling of metaplastic lineages identifies CDH17 as a prognostic marker in early stage gastric cancer. , 2010, Gastroenterology.

[34]  Y. Jeng,et al.  Cadherin-17 is a useful diagnostic marker for adenocarcinomas of the digestive system , 2008, Modern Pathology.

[35]  E. Gamelin,et al.  Clinical pharmacokinetics of oxaliplatin: a critical review. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[37]  E. J. Neves,et al.  Molecular Classifiers for Gastric Cancer and Nonmalignant Diseases of the Gastric Mucosa , 2004, Cancer Research.

[38]  Y. Benjamini,et al.  Controlling the false discovery rate in behavior genetics research , 2001, Behavioural Brain Research.

[39]  D. Botstein,et al.  Variation in gene expression patterns in human gastric cancers. , 2003, Molecular biology of the cell.

[40]  Rui Li,et al.  Comprehensive analysis of the gene expression profiles in human gastric cancer cell lines , 2002, Oncogene.

[41]  M. Koike,et al.  Differences in the mode of the extension of gastric cancer classified by histological type: new histological classification of gastric carcinoma. , 1992, Gut.

[42]  M. Salto‐Tellez,et al.  CD133 expression predicts for non-response to chemotherapy in colorectal cancer , 2010, Modern Pathology.

[43]  S. Bianchi,et al.  Reproducibility of histologic classification of gastric cancer. , 1991, British Journal of Cancer.

[44]  C. V. D. Velde,et al.  Gastric cancer , 2009, The Lancet.

[45]  J. Llovet,et al.  Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. , 2010, Seminars in liver disease.

[46]  Kazuhiro Yoshida,et al.  Clinicopathological significant and prognostic influence of cadherin-17 expression in gastric cancer , 2005, Virchows Archiv.

[47]  A. Ohtsu,et al.  Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. , 2009, The Lancet. Oncology.